A BILL 
To amend the Public Health Service Act to provide for 
stockpiles to ensure that all Americans have access to 
generic drugs at risk of shortage, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Essential Medicines 
4
Strategic Stockpile Act of 2021’’. 
5
02:51 Jun 08, 2021
H2870
2 
•HR 2870 IH
SEC. 2. PILOT PROGRAM ON ENSURING MEDICATION SUP-
1
PLY STABILITY. 
2
Part D of the Public Health Service Act (42 U.S.C. 
3
254b et seq.) is amended by adding at the end the fol-
4
lowing new subpart: 
5
‘‘Subpart XIII—Ensuring Medication Supply Stability 
6
‘‘SEC. 340J. ENSURING MEDICATION SUPPLY STABILITY. 
7
‘‘(a) AWARD OF CONTRACTS.—Beginning not later 
8
than January 1, 2022, the Secretary shall award contracts 
9
to eligible entities to each implement and test the effective-
10
ness of acquiring, maintaining, managing, and distrib-
11
uting a stockpile that— 
12
‘‘(1) consists of generic drugs at risk of short-
13
age; and 
14
‘‘(2) is of sufficient quantity to ensure that cus-
15
tomers in the United States have access to such 
16
drugs for at least 6 months (as specified by the Sec-
17
retary based on the historic demand for those 
18
drugs). 
19
‘‘(b) SELECTION OF DRUGS.— 
20
‘‘(1) IN GENERAL.—The Secretary shall— 
21
‘‘(A) select not more than 50 drugs that 
22
may be included by eligible entities in a stock-
23
pile pursuant to a contract under this section; 
24
and 
25
02:51 Jun 08, 2021
H2870
3 
•HR 2870 IH
‘‘(B) maintain an up-to-date list of such 
1
drugs; and 
2
‘‘(C) make such list publicly available. 
3
‘‘(2) CHOICE OF ELIGIBLE ENTITIES.—A con-
4
tract awarded to an eligible entity under this section 
5
need not require the stockpile of the eligible entity 
6
to include all 50 drugs listed pursuant to paragraph 
7
(1). 
8
‘‘(c) SUFFICIENT QUANTITY.—For each generic drug 
9
listed pursuant to subsection (b)(1), the Secretary shall 
10
specify the quantity of such drug that is sufficient to en-
11
sure that consumers in the United States have access to 
12
such drug for at least 6 months. 
13
‘‘(d) DURATION; LIQUIDATION OF INVENTORY.— 
14
‘‘(1) DURATION.—A contract awarded under 
15
this section shall be for a term of no more than 3 
16
years. 
17
‘‘(2) LIQUIDATION
OF
INVENTORY.—A drug 
18
held in a stockpile pursuant to a contract under this 
19
section may be liquidated by the eligible entity at the 
20
end of the period of the contract. 
21
‘‘(e) STOCKPILE REQUIREMENTS.— 
22
‘‘(1) ENSURING AVAILABILITY OF UNEXPIRED 
23
PRODUCTS.—Each eligible entity with a contract 
24
02:51 Jun 08, 2021
H2870
4 
•HR 2870 IH
under this section for a stockpile of generic drugs at 
1
risk of shortage shall— 
2
‘‘(A) ensure that each drug maintained in 
3
the stockpile has an expiration date at least 1 
4
year beyond the current date; and 
5
‘‘(B) to comply with subparagraph (A)— 
6
‘‘(i) sell drugs in the stockpile through 
7
normal commercial channels and replace 
8
those drugs; or 
9
‘‘(ii) if there is no commercial market 
10
for a drug in the stockpile, dispose of the 
11
drug and report such disposal to the Sec-
12
retary. 
13
‘‘(2) MANAGEMENT OF STOCKPILE.— 
14
‘‘(A) IN
GENERAL.—The Secretary shall 
15
ensure that— 
16
‘‘(i) collectively, the eligible entities 
17
with contracts under this section for a 
18
stockpile of generic drugs at risk of short-
19
age acquire, not later than 6 months fol-
20
lowing the date set in such contracts, and 
21
maintain thereafter, a 6-month supply of 
22
such drugs; and 
23
‘‘(ii) the 6-month supply required by 
24
clause (i) is in addition to the average lev-
25
02:51 Jun 08, 2021
H2870
5 
•HR 2870 IH
els of inventory held by eligible entities 
1
over the previous year for the respective 
2
drugs. 
3
‘‘(B) INVENTORY MANAGEMENT.—Each el-
4
igible entity with a contract under this section 
5
for a stockpile of generic drugs at risk of short-
6
age shall manage inventory to ensure that 
7
drugs in the stockpile are efficiently cycled to 
8
the commercial market. 
9
‘‘(C) ANNUAL
AUDITS.—Not more than 
10
annually, the Secretary may request a physical 
11
audit count of the inventories of all eligible enti-
12
ties with a contract under this section to vali-
13
date that each such entity is maintaining the 
14
appropriate amount of stockpiled inventory. 
15
‘‘(3) REPORTING.—Each eligible entity with a 
16
contract under this section shall submit reports at 
17
such time and in such manner as the Secretary may 
18
require regarding— 
19
‘‘(A) current inventory levels of stockpiled 
20
drugs at a drug level; 
21
‘‘(B) indicators of current inventory levels 
22
of stockpiled drugs relative to acceptable mini-
23
mums; and 
24
02:51 Jun 08, 2021
H2870
6 
•HR 2870 IH
‘‘(C) such other matters as the Secretary 
1
determines appropriate. 
2
‘‘(f) CONTRACT TERMS.— 
3
‘‘(1) PAYMENT OF MONTHLY FEES FOR MAN-
4
AGEMENT.—Subject to paragraph (2), the Secretary 
5
shall pay to each eligible entity with a contract 
6
under this section for a stockpile of generic drugs at 
7
risk of shortage appropriate monthly fees for the 
8
management of the stockpile. 
9
‘‘(2) PAYMENT
CONDITIONED
ON
STOCKPILE 
10
ADEQUACY.— 
11
‘‘(A) IN GENERAL.—Except as provided in 
12
subparagraph (B), each contract with an eligi-
13
ble entity under this section shall provide that 
14
no payment under the contract may be made 
15
until the entity demonstrates to the Secretary 
16
that the entity has stockpiled such portion of 
17
the total quantity of drugs to be stockpiled 
18
under the contract as the Secretary determines 
19
to be acceptable for payment. 
20
‘‘(B) EXCEPTIONS
FOR
ADVANCE
PAY-
21
MENTS.— 
22
‘‘(i) IN GENERAL.—A contract under 
23
this section may provide that, if the Sec-
24
retary determines (in the Secretary’s dis-
25
02:51 Jun 08, 2021
H2870
7 
•HR 2870 IH
cretion) that an advance payment, partial 
1
payment for significant milestones, or pay-
2
ment to increase capacity is necessary to 
3
ensure success of the terms of the con-
4
tract, the Secretary shall pay, in advance 
5
of delivery, an amount not to exceed 10 
6
percent of the total contract amount to be 
7
paid to the eligible entity by the Secretary 
8
pursuant to the contract over the full pe-
9
riod of the contract. 
10
‘‘(ii) COST OF CAPITAL.—A contract 
11
under this section may provide for pay-
12
ments to compensate the contracting eligi-
13
ble entity for additional capital require-
14
ments related to the additional inventory 
15
to be maintained. 
16
‘‘(iii) TIMING.—The Secretary shall, 
17
to the extent practicable, make any deter-
18
mination under clause (i) to make an ad-
19
vance payment at the same time as the 
20
issuance of a solicitation. 
21
‘‘(iv) REPAYMENT.—If the Secretary 
22
makes an advance payment pursuant to 
23
clause (i), the Secretary shall require the 
24
eligible entity receiving such advance pay-
25
02:51 Jun 08, 2021
H2870
8 
•HR 2870 IH
ment to repay it if there is a failure to per-
1
form by the eligible entity. 
2
‘‘(3) TERMINATION.—Nothing in this section 
3
shall be construed as affecting the rights of eligible 
4
entities under provisions of statute or regulation (in-
5
cluding the Federal Acquisition Regulation) relating 
6
to the termination of contracts for the convenience 
7
of the Government. 
8
‘‘(g) CONGRESSIONAL OVERSIGHT.— 
9
‘‘(1) INDEPENDENT
EVALUATION
AND
RE-
10
11
actment of this section and annually thereafter, the 
12
Comptroller General of the United States shall con-
13
duct an independent evaluation, and submit to the 
14
appropriate congressional committees a report, con-
15
cerning the program under this section. 
16
‘‘(2) CONTENTS OF REPORT.—The report under 
17
paragraph (1) shall review, assess, and provide rec-
18
ommendations, as appropriate, on the following: 
19
‘‘(A) Details on likely costs and resultant 
20
savings as compared to a stockpiling method 
21
that does not incorporate perpetual inventory 
22
cycling. 
23
02:51 Jun 08, 2021
H2870
9 
•HR 2870 IH
‘‘(B) Identification of drawdowns from the 
1
stockpile, as evidence of market shortage avoid-
2
ance. 
3
‘‘(C) The allocation of drugs included in 
4
the stockpiles funded pursuant to this section to 
5
the customers of the eligible entities with con-
6
tracts under this section. 
7
‘‘(D) The degree to which eligible entities 
8
with contracts under this section fulfilled their 
9
obligations under such contracts. 
10
‘‘(h) DEFINITIONS.—In this section: 
11
‘‘(1) The term ‘eligible entity’ means an entity 
12
that meets each of the following criteria: 
13
‘‘(A) The entity is licensed or registered in 
14
accordance with applicable Federal and State 
15
law and in good standing with respect to such 
16
licensure or registration. 
17
‘‘(B) If the entity is not a manufacturer, 
18
the entity agrees— 
19
‘‘(i) to purchase all drugs to be main-
20
tained in its stockpile funded under this 
21
section directly from the manufacturers of 
22
the drugs or the exclusive distributors of 
23
such manufacturers; or 
24
02:51 Jun 08, 2021
H2870
10 
•HR 2870 IH
‘‘(ii) in the case of an entity that is a 
1
co-op or chain pharmacy warehouse— 
2
‘‘(I) to purchase drugs to be 
3
maintained in its stockpile funded 
4
under this section from an authorized 
5
distributor; and 
6
‘‘(II) distribute those drugs only 
7
to its member pharmacies. 
8
‘‘(C) The entity sells more than 90 percent 
9
of its drugs to dispensers. 
10
‘‘(D) The entity agrees to distribute inven-
11
tory from its stockpile funded under this section 
12
only to wholesale distributors or dispensers that 
13
are customers of the entity. 
14
‘‘(2) The term ‘generic drug at risk of shortage’ 
15
means a drug (as defined in section 201 of the Fed-
16
eral Food, Drug, and Cosmetic Act) that— 
17
‘‘(A) is approved pursuant to section 
18
505(j) of such Act; 
19
‘‘(B) is included in the list of essential 
20
medicines published by the Food and Drug Ad-
21
ministration; 
22
‘‘(C) is included, at any point during the 
23
preceding 36 months, on the drug shortage list 
24
02:51 Jun 08, 2021
H2870
11 
•HR 2870 IH
in effect under section 506E of the Federal 
1
Food, Drug, and Cosmetic Act; and 
2
‘‘(D) is manufactured by 3 or fewer per-
3
sons that are registered under section 510 of 
4
the Federal Food, Drug, and Cosmetic Act for 
5
purposes of such manufacture. 
6
‘‘(i) AUTHORIZATION
OF
APPROPRIATIONS.—To 
7
carry out this section, there is authorized to be appro-
8
priated $120,000,000 for fiscal years 2022 through 2024, 
9
to remain available until expended.’’. 
10
Æ 
02:51 Jun 08, 2021
H2870
